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Abstract
Background: An important mechanism for gene regulation utilizes small non-coding RNAs called
microRNAs (miRNAs). These small RNAs play important roles in tissue development, cell
differentiation and proliferation, lipid and fat metabolism, stem cells, exocytosis, diseases and
cancers. To date, relatively little is known about functions of miRNAs in the lung except lung
cancer.
Results: In this study, we utilized a rat miRNA microarray containing 216 miRNA probes, printed
in-house, to detect the expression of miRNAs in the rat lung compared to the rat heart, brain, liver,
kidney and spleen. Statistical analysis using Significant Analysis of Microarray (SAM) and Tukey
Honestly Significant Difference (HSD) revealed 2 miRNAs (miR-195 and miR-200c) expressed
specifically in the lung and 9 miRNAs co-expressed in the lung and another organ. 12 selected
miRNAs were verified by Northern blot analysis.
Conclusion: The identified lung-specific miRNAs from this work will facilitate functional studies
of miRNAs during normal physiological and pathophysiological processes of the lung.
Background
MicroRNAs (miRNAs) include a large group of regulatory,
non-coding small RNAs that measure ~22 nucleotides
(nt) in length [1,2]. In animal cells, miRNAs are first tran-
scribed from genes by the RNA polymerase, pol II, as pri-
mary miRNAs, which are then cleaved by an RNase III
enzyme, Drosha, into hairpin-like precursor miRNA (pre-
miRNA) [3]. The pre-miRNAs are transported into the
cytoplasm with the help of a protein called Exportin 5 [4]
In the cytoplasm, the pre-miRNAs are cut into double
stranded RNA duplexes by another RNase III enzyme,
Dicer [5]. Typically, one of the strands becomes mature
miRNA and is incorporated into a RISC complex with
other components for target recognition [6]. The RISC
complex then binds to its target mRNA through base pair-
ing and carries out its functions. Customarily, in the target
mRNAs of an animal miRNA, there are multiple comple-
mentary sites, which correspond to the same miRNA. This
cooperative action makes inhibition more efficient [7,8].
On the other hand, one miRNA usually inhibits multiple
target mRNAs [9,10]. This property enables miRNA to reg-
ulate many genes in a pathway or physiological process at
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target mRNA, translational inhibition, and mRNA deade-
nylation [11-15]. Several studies have shown that the
degree of complementarity between the miRNA and its
target determines the mode of how a miRNA works
[11,13-16]. Since the discovery of the first miRNA, lin-4
[9], much progress has been made in the elucidation of
miRNA mechanisms [1,2,9,17-20]. However, only a
handful of miRNAs have been studied for their precise
functions. The miRNAs in animals function in tissue
development, cell differentiation, apoptosis, fat and lipid
metabolism, exocytosis, stem cell division and differenti-
ation, diseases and cancers [17,21-33]. These known func-
tions may represent just a small part of a much bigger
picture. One third of the genes in the human genome are
predicted to miRNA targets [34]. With the continuing dis-
covery of new miRNA functions, it is possible that miR-
NAs will be associated with the regulation of almost every
aspect of cell physiology.
Spatial and temporal expression patterns of miRNAs can
provide clues for their possible functions. Profile studies
have already shown that many miRNAs are specifically
expressed in certain organs, cell types and developmental
stages. In a recent study, miRNA expression patterns
among different pancreas cell types were compared [28].
One of the detected miRNAs in the study was identified as
a pancreas islet-specific miRNA, which was later demon-
strated to function in insulin secretion [28].
In order to study the expression profiling of miRNAs in
mice and humans, several high throughput platforms
have been developed. Microarrays on either membranes
or slides are widely used for this purpose [35-43]. Various
probe designs and labeling methods have also been uti-
lized. Some groups have applied these microarray meth-
ods in an effort to detect the expression profiling of
miRNAs in different tissues and cell types in humans and
mice. Real-time PCR has also been used to detect the
expression of pre-mRNAs and mature miRNAs [44,45].
The purpose of this study is to identify miRNAs that are
expressed specifically in the rat lung or co-expressed in the
lung and one of the five other organs in the rat. In addi-
tion, this study aims to set up a reliable, in-house miRNA
microarray platform for lung research. Although the
expression profiling of miRNAs in human and mouse
organs has been detected by some groups, the expression
in rat organs has not been extensively studied. Further-
more, relatively little is known about the detailed func-
tions of miRNAs in the lung except lung cancers. For this
study, we designed a probe set for rat miRNAs as well as
human and mouse miRNAs that possess conservative
sequences in the rat genome, based on the fact that miR-
NAs are highly conserved in animals and in plants [46-
51]. The hybridizations were performed with slides
printed in our laboratory. The reliability of the microarray
platform was tested before other experiments were per-
formed. As a result, our microarray allowed us to identi-
fied lung-specific miRNAs in the rat that are likely to
facilitate studies of miRNA functions in the lung.
Results
Reproducibility and specificity of the miRNA microarray 
platform
In order to evaluate the reliability of the miRNA micro-
array, we tested the reproducibility of the data from mul-
tiple hybridizations (Figure 1). First, equal amounts of
enriched miRNAs from each of the 6 organs were pooled
as the common reference. Then, miRNA from each organ
(Cy3) was co-hybridized with the common reference
(Cy5). The maximum and minimum probe signals in the
six replicates from each hybridization were excluded from
data analysis. The miRNA signal was then calculated as the
geometric average of the remaining 4 probe signals. The
correlation coefficient of the miRNA signals of the com-
mon references (Cy5) between two hybridizations was
calculated in order to assess the reproducibility of the
microarray hybridization. The results are shown in Table
1. The correlation coefficients between two hybridizations
were 0.89 – 0.98. For comparison, we also used one spot
per block for calculations, where the correlation coeffi-
cients were 0.83 to 0.95. The results suggest that our arrays
are highly reproducible.
To test the specificity of the microarray, we used mis-
matched probes for two miRNAs, rno-miR-16 and rno-miR-
324-5p, which were included in the control oligos pro-
vided with the labeling kit. The probes with one, two and
three nucleotide mismatches were denoted with m1, m2
and m3, respectively. The microarray could not reliably
distinguish those with only one mismatch. However, the
signals from probes with two mismatches were signifi-
cantly decreased, >20 fold less than those from probes
with perfect base paring (Figure 2). From these results, we
concluded that our microarray could differentiate
between miRNAs with two or more nucleotide differ-
ences.
Identification of lung-specific miRNA
In order to identify miRNAs that are prominently
expressed in the rat lung or co-expressed in the lung and
another organ, miRNA samples from 6 organs of 4 rats
were co-hybridized with the common reference. A dye flip
was subsequently performed. After scanning the slides,
spots qualities were evaluated using the Realspot software
[52]. Any miRNAs with average QI's no larger than 1 in
any of the six organs were eliminated from data analysis.
Out of 216 miRNAs, only 127 passed the Realspot quality
test. The qualified miRNA signals were then tested by Sig-Page 2 of 14
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miRNA microarray fabrication and hybridization strategyFigure 1
miRNA microarray fabrication and hybridization strategy. (A) The probes were two copies of antisense oligos of 
mature miRNA. The 5' ends of the probes were amino modified. The probes were linked to epoxy-coated slides covalently. 
miRNA samples were tagged and hybridized to the slides. (B) Each slide contained three identical blocks and each block was 
hybridized with two-colored paired samples. There were 6 duplicated probes for each miRNA as shown in block A. MIR xxxx, 
series number.
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NAs that did not have significant changes between any of
the six organs [53]. After the SAM test, another 21 miRNAs
were eliminated, leaving 106 miRNAs for further study.
Any miRNAs that were prominent in one organ or co-
expressed in two organs were identified by Tukey Hon-
estly Significant Difference (HSD) analysis (P < 0.05)
(Tables 2, 3, and Figure 3). Two miRNAs (rno-miR-195
and rno-miR-200c) were identified as being expressed spe-
cifically in the rat lung. There are 5 and 3 nucleotide dif-
ferences between miR-200c, and miR-200a and miR-200b,
respectively. Therefore, our arrays were able to detect the
difference between the isoforms. The numbers of the
prominently expressed miRNAs in the heart, brain, liver,
kidney and spleen were 6, 13, 5, 2 and 18, respectively.
The numbers of co-expressed miRNAs are shown on the
lines between the two organs in Figure 3. The lung had
more miRNAs co-expressed in the heart than with any
other organ. This finding is likely due to the relationship
between the lung and the heart in organogenesis.
After HSD analysis, we calculated the organ specificity
index (OSI) for organ-miRNAs that passed the SAM test.
There were 2, 5, 18, 5, 1, and 16 miRNAs prominently
expressed in the lung, heart, brain, liver, kidney and
spleen, respectively using OSI >0.90 as a criterion (Table
2). We also noted organ specificity if the miRNA expres-
sion in one organ was at least two fold of that in all other
organs. According to this two-fold definition, similar
results were obtained (Table 2), showing the number of
miRNAs exclusively expressed in only one of the 6 organs
to be 2 (lung), 5 (heart), 14 (brain), 5 (liver), 2 (kidney),
and 15 (spleen).
Confirmation by Northern blot
To further investigate the reliability of our microarray
data, 12 miRNAs were selected for Northern blot confir-
mation (Figure 4). Total RNA was extracted from the lung,
heart, brain, liver, kidney and spleen from 4 rats. These
were the same tissues from the rats utilized for small RNA
extraction for the microarray experiment. Total RNA sam-
ples from the respective organs were pooled for the exper-
iment. The intensities of the blots were normalized to U6
snRNA and the normalized intensities from Northern
blots were compared with those from the arrays (Figure
5). Among the 12 selected miRNAs, two were lung-spe-
cific (miR-195 and miR-200c), one was kidney-specific
(miR-10a), and three were co-expressed in the lung and
heart (miR-126, miR-143 and miR-145) as determined by
HSD, OSI and two-fold criteria. Most miRNAs had similar
expression patterns from microarray analysis and North-
ern blots (Figure 4a–c). In a few cases, the Northern blot
showed a higher expression in comparison with the
microarray, including miRNA-195 in heart and miRNA-
145 in kidney and spleen. We also selected additional
miRNAs for verification: 3 miRNAs that had high expres-
sion in the lung and/or heart (Figure 4d and 5d) and 3
miRNAs that were expressed in most of the 6 organs (Fig-
ure 4e and 5d). Again, the results exhibited the consist-
ency of the expression patterns between the miRNA array
and Northern blot analysis. The correlation coefficients of
7 miRNAs between microarray and Northern blot were
higher than 0.9. Although there were few discrepancies, it
is clear that the microarray data agreed with the Northern
blot data.
Discussion and conclusion
In this study, we designed a miRNA microarray system in
our laboratory and tested its reliability. This method was
used to compare the miRNA expression patterns of six dif-
ferent rat organs, namely the lung, heart, brain, liver, kid-
ney and spleen. We identified 2 miRNAs (miR-195 and
miR-200c) that were distinctively expressed in the rat lung,
8 miRNAs that were co-expressed in the lung and heart
and 1 miRNA that was co-expressed in the lung and kid-
ney. The reliability of our microarray was confirmed by
the high consistence between the microarray and North-
ern blot analysis.
Several groups have developed miRNA microarray plat-
forms to detect the profiling of miRNAs. However, our
platform has several unique features. First, we used two-
channel co-hybridization. We also pooled all of the sam-
ples as the common reference. Additionally, we per-
formed the dye swap to eliminate the effect of dye bias.
The approaches are similar to those used in DNA microar-
rays. Conversely, most of the other platforms use a single
channel platform. Some groups have utilized synthesized
Table 1: The correlation coefficients of common reference signals between two hybridizations
lung heart brain liver kidney
heart 0.984393
brain 0.980202 0.973659
liver 0.973702 0.97738 0.965574
kidney 0.96804 0.971573 0.965264 0.978328
spleen 0.895349 0.893531 0.92511 0.917216 0.925989
Cy3-labeled organ and Cy5-labeled common reference (pooled samples from 6 organs) were co-hybridized. The correlation coefficients were 
calculated from the log2 transformed average signals of the common reference between two hybridizations.Page 4 of 14
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BMC Genomics 2007, 8:29 http://www.biomedcentral.com/1471-2164/8/29oligos as the common reference in their microarrays
[37,43], but the DNA-RNA hybridization may differ from
DNA-DNA hybridization. Second, we have 6 replicate
spots in our microarray, making us able to exclude the
maximum and minimum values while being able to cal-
culate the geometric average signal from the remaining 4
replicates. This method significantly increased the repro-
ducibility of the data. Third, we printed slides in-house
with 3 identical blocks in each slide. This procedure
allowed us to hybridize 6 samples (3 pairs) on a single
slide. We have previously demonstrated that this
approach significantly reduces the variance and increases
the efficiency [54].
When comparing our data with previous studies, there are
similarities as well as differences. For example, only one of
the miRNAs we identified as lung-specific, miR-200c, has
been reported by other groups [37]. Also, miR-195 was
previously reported to be expressed higher in the spleen
than in the lung [37], but both our microarray and North-
ern blot results show rno-miR-195 expressing much higher
in the lung than in the spleen. A few factors could have
lead to these discrepancies. First, the miRNAs printed on
our microarray slides were different from others. Some
platforms did not contain all of the 217 miRNAs that we
printed on our slides. For example, mmu-miR-375 is a
newly identified miRNA expressed highly in the lung. This
particular miRNA was not included on microarray slides
in the other studies. Therefore, our study is supplemental
and concurrent with other miRNA profiling studies. Sec-
ond, the sample origins, hybridization conditions, and
data analysis methods were different among different
research groups. Our miRNA samples were extracted from
rat organs and those of other groups were extracted from
Specificity of miRNA microarray hybridizationFigure 2
Specificity of miRNA microarray hybridization. The control oligos in the 3 DNA array900 microRNA direct kit were 
ligated with Cy5 capture sequence and hybridized onto one block. The mismatched probes had one (m1), two (m2) or three 
(m3) mismatched nucleotides with the corresponding control oligos. The signals from the slide were processed with the 
method described in Materials and Methods. Data shown were means ± S.E. from 3 hybridizations.Page 5 of 14
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Table 2: Organ-specific microRNAs identified by HSD test, OSI test and two-fold criteria.
Lung (2) Heart (6) Brain (13) Liver (5) Kidney (2) Spleen (18)
OSI 2 fold OSI 2 fold OSI 2 fold OSI 2 fold OSI 2 fold OSI 2 fold
mo-miR-195 0.957 ✔ mmu-miR-1 0.999 ✔ mmu-miR-9* 0.999 ✔ mo-miR-101b 0.998 ✔ mo-miR-10a 0.975 ✔ mmu-miR-17-5p 0.983 ✔
mo-miR-200c 0.973 ✔ mmu-miR-133b 0.998 ✔ mo-miR-103 0.902 mo-miR-122a 1.000 ✔ mo-miR-10b 0.899 mmu-miR-207 0.973 ✔
mo-miR-133a 0.999 ✔ mo-miR-107 0.967 ✔ mo-miR-192 0.956 ✔ mo-miR-200b† 0.900 ✔ mo-miR-106b 0.911
mo-miR-208 0.999 ✔ mo-miR-124a 1.000 ✔ mo-miR-194 0.914 ✔ mo-miR-142-5p 0.976 ✔
mo-miR-22 0.975 ✔ mo-miR-127 0.995 ✔ mo-miR-31 0.994 ✔ mo-miR-150 0.992 ✔
mo-miR-27a 0.886 mo-miR-128a 1.000 ✔ mo-miR-15b 0.895
mo-miR-128b† 0.964 ✔ mo-miR-16 0.857
mo-miR-130a 0.940 ✔ mo-miR-17 0.971 ✔
mo-miR-132 0.999 ✔ mo-miR-187 0.990 ✔
mo-miR-137† 0.958 ✔ mo-miR-191 0.944 ✔
mo-miR-138 0.980 ✔ mo-miR-20 0.982 ✔
mo-miR-181a 0.925 ✔ mo-miR-206 0.998 ✔
mo-miR-218 0.982 ✔ mo-miR-210 0.997 ✔
mo-iR-221† 0.916 mo-miR-297 0.997 ✔
mo-miR-29b 0.981 ✔ mo-miR-328 0.980 ✔
mo-miR-29c† 0.906 mo-miR-333 0.997 ✔
mo-miR-9 1.000 ✔ mo-miR-346 0.995 ✔
mo-miR-93 0.944 ✔
The numbers in the parenthesis are the quantities of the microRNAs identified by HSD test. The listed miRNAs were identified by HSD except those marked by "†". The symbol, "✔" indicates the 
organ-specific miRNAs that were identified by two-fold criteria. A OSI of >0.9 was considered as organ-specific.
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differences, most miRNAs identified thus far are con-
served among species. The use of different hybridization
conditions and normalization methods may have also
caused some inconsistencies in sensitivity and specificity.
However, the methods and conditions used in our study
are highly reproducible. Third, some miRNAs that were
lung-specific were not highly expressed. This may have
caused a disagreement with other microarray platforms.
Indeed, when we compared the highly expressed miRNAs
that we found in the rat brain to those identified by other
groups, 11 out of 13 were consistent with others
[35,37,43,55], suggesting that our results are reliable and
comparable to other miRNA microarray platforms.
There are some differences between the results from the
microarray and the Northern blots. The most obvious rea-
son for the variation was that the hybridization condi-
tions and the normalization methods were different
between the two. The hybridization temperatures and
buffer affected the sensitivity and specificity of the assays.
The assumption for the microarray normalization was
that the total amount of miRNA was consistent between
samples from different organs. Realistically, this assump-
tion was not true in some cases. The signals from the
Northern blots were normalized to the signals of U6
snRNA with the assumption that the amount of U6
snRNA was the same as the amount of total RNA from the
different organs. It is virtually impossible to provide the
exact same amount of RNA between samples.
Among the 12 miRNAs confirmed by the Northern blots,
none has a known function except mmu-miR-375 [28].
The expression of mmu-miR-375 was reported to be lim-
ited to the pancreatic β cells, although we also detected it
in the rat lung. It has been reported to regulate the secre-
tion of insulin. Neither the secondary signals nor the actin
filament network are affected by mmu-miR-375. Mtpn was
validated as a target gene of mmu-miR-375. Mtpn was
reported to form a complex with CapZ which regulates
actin polymerization [56]. In the lung, the alveolar epithe-
lial type II cells secrete surfactant through exocytosis,
which helps to reduce the surface tension of the alveolar
sacs and facilitate the normal function of gas exchange.
The mechanism of the secretion of surfactant in the lung
is similar to that of the secretion of insulin in the pancreas.
We suspect that mmu-miR-375 works in both of these exo-
cytosis processes. We may find some hints as to the mech-
anism of exocytosis in the lung if we find more targets of
miR-375 or any of the components that interact with these
targets.
Two well-known miRNAs, miR-1 and miR-133, have
highly specific expression in cardiac and skeletal muscle
tissue [55]. In our study, we also identified these miRNAs
as having heart-specific expression. These two miRNAs are
clustered together in the mouse genome and both of them
modulate muscle proliferation and differentiation. miR-1
promotes myogenesis by targeting histone deacetylase 4
(HDAC4), while miR-133 promotes myoblast prolifera-
tion by inhibiting serum response factor (SRF) [57].
A brain-specific miRNA, miR-9, has been identified by our
microarray as well as by microarrays from other groups. It
has been shown to affect neural lineage differentiation in
ES cells. STAT3, which is a member of the signal trans-
ducer and activator of transcription family, is believed to
be involved in this function [27]. In presenilin-1 null
mice, miR-9 has been shown to be down-regulated, lead-
ing to severe brain developmental defects [38].
The liver-specific miRNA, miR-122, likely modulates the
hepatitis C virus by facilitating replication of the viral
RNA. Mutational analysis and ectopic expression studies
have revealed that miR-122 interacts with the 5' non-cod-
ing region of the viral genome [58]. This suggests that
miR-122 may be a target for antiviral interaction [58]. In
addition, miR-122 is a key regulator of cholesterol and
Table 3: miRNAs co-expressed in two organs
lung-heart lung-brain lung-kidney heart-brain heart-spleen brain-liver liver-kidney liver-spleen
2-fold 2-fold 2-fold 2-fold 2-fold 2-fold 2-fold 2-fold
mmu-miR-322-5p† √ rno-miR-125a† √ rno-miR-10a rno-miR-29b √ mmu-miR-1† √ rno-miR-128b √ rno-miR-192 √ rno-miR-122a √
mo-miR-126 √ mo-miR-29c† √ rno-miR-194 √
mo-miR-143 √
mo-miR-145 √
mo-miR-23a √
mo-miR-23b √
mo-miR-24
mo-miR-27a √
mo-miR-27b
The listed miRNAs co-expressed in two organs were identified by HSD except those marked with "†". The symbol "√" indicates the miRNAs that 
were identified by 2 fold criteria.Page 7 of 14
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BMC Genomics 2007, 8:29 http://www.biomedcentral.com/1471-2164/8/29fatty-acid metabolism in the adult liver by regulating
plasma cholesterol levels, fatty-acid oxidation, hepatic
fatty-acid synthesis as well as cholesterol synthesis [22].
Among the spleen-specific miRNAs identified, five of
them belong to the mir17 miRNA cluster, which comprise
miR-17, miR-18, miR-19a, miR-19b, miR-20, miR-25, miR-
92, miR-93, miR-106a, and miR-106b [59]. Among these 5
miRNAs, miR-17-5p, miR-17 and miR-20 belong to one of
the mir17 microRNA clusters, the mir-17–92 cistron,
which is one with well characterized cancer association.
The mir-17–92 polycistron is located at 13q31, a genomic
locus that is often amplified in cancers. The substantial
increase in the expression of microRNAs from this cistron
has been reported in human B-cell lymphomas and
human lung cancers [60,61]. However, the prominent
expression and function of these miRNAs in the spleen are
not known.
There are few studies concerning the functions of miRNAs
in the lung. Several recent studies have given rise to a great
interest in this field of research. The reduction in the
expression of let-7 in human lung cancers is correlated to
increased death rates in patients [62]. Experimentally,
over-expression of let-7 can inhibit lung cancer cell growth
in vitro. This discovery shows that let-7 may have potential
clinical value in treating lung cancers. Inactivation of
Dicer results in the defect of epithelial branching [63].
This defect is independent of the requirement for Dicer in
cell survival and does not stop the epithelial growth [63].
In the E11.5 lung, Ago1 and Ago2 are enriched in the
branching regions, which undergo the most dynamic
changes during lung remodeling. This discovery suggests
that miRNAs regulate processes responsible for the bio-
genesis of the lung [64]. Another study shows that the
decrease in Dicer expression is associated with the poor
prognosis in lung cancer patients [65]. The miRNA expres-
sion profiles in lung cancers correlate with the prognosis
of lung adenocarcinoma patients [66].
In summary, we designed a reliable miRNA microarray
platform that is low in cost and easy to update with highly
reproducible results. The expression profiling of microR-
NAs in 6 rat organs was detected with this platform. The
expression patterns of lung-specific and lung co-expressed
microRNAs were confirmed by Northern blot analysis.
Our platform adds to the implementation of detecting
microRNA profiles, as no other microarray platform has
been made for the detection of rat microRNA profiles. Fur-
thermore, our microarray platform contains several
recently discovered miRNAs, making it supplementary to
other platforms. When applied, our study of the expres-
sion patterns of miRNAs in the lung should shed light on
the functions of miRNAs in lung physiology as well as
lung pathophysiology.
Methods
Microarray fabrication
217 mature miRNA sequences were downloaded from the
miRNA registry (Wellcome Trust Sanger Institute). 177 of
these were from rat, and 40 non-redundant conservative
ones were from human or mouse. Sequences of some of
these human and mouse miRNAs did not match their cor-
responding sequence in the rat genome exactly and were
modified in accordance with those in the rat genome. The
probes for the miRNAs had two copies of antisense
sequences (34–50 nt) (Figure 1A). Probe sets, which con-
tained 5' amino modified C6 oligos were synthesized by
Sigma-Genosys (Woodlands, TX) at 100 μM concentra-
tion and suspended in 3 × SSC buffer. The oligos were
diluted to 25 μM with 3 × SSC prior to use. The probes
were then printed onto epoxy-coated slides (CEL Associ-
ates, Pearland, TX) with an OmniGrid 100 array (Gen-
eMachine, San Carlos, CA) at 65% humidity and then
incubated for 48 hours at the same humidity. Each slide
contained three identical blocks in a landscape orienta-
tion. Within each block every probe was printed 6 times
in 3 separate pairs (Figure 1B). The oligo set also con-
tained one probe for U6 and 3 probes for tRNAs as posi-
tive controls as well as one probe for a plant miRNA as a
negative control.
Tissue sample and small RNA extraction
Four male Sprague-Dawley rats (200 g, Charles River Lab-
oratories, Inc., Wilmington, MA) were anaesthetized. The
six organs (lung, heart, brain, kidney, liver and spleen)
were collected and powdered in liquid nitrogen. Small
RNA was enriched from the powdered samples from the 6
rat organs using the mirVana™ microRNA isolation kit
from Ambion (Austin, TX), according to the manufac-
turer's protocol. First, 200 mg powder was homogenized
in 2 ml Lysis/Binding Buffer. Then, one-tenth of the vol-
ume of miRNA homogenate additive was added to the
homogenate and a volume of acid-phenol: chloroform
was used to extract RNA. One-third volume of 100% eth-
anol was added to the aqueous phase, and the sample was
passed through a filter cartridge. Two-thirds volume of
100% ethanol was then added to the filtrate, and the sam-
ple was passed through a second filter cartridge. The sec-
ond filter cartridge was subsequently washed once with
wash solution 1 and then twice with Wash Solutions 2
and 3. Afterwards, the small RNA was eluted with 95°C
nuclease-free water. Total RNA for Northern blots was also
extracted from these organs by the aforementioned proto-
col. Following organic extraction, one and one-forth vol-
umes of 100% ethanol was added to the aqueous phase.
The lysate/ethanol mixture was then passed through a fil-
ter cartridge. The cartridge was washed, and the total RNA
was eluted with water as described above. The concentra-
tion of RNA was determined by a NanoDrop ND-1000
Spectrophotometer (NanoDrop Tech., Rockland, DE).Page 8 of 14
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Organ-specific microRNAsFigure 3
Organ-specific microRNAs. (A) Hot maps. The microRNA samples from 6 organs were co-hybridized with the common 
reference. The signals were processed as described in Materials and Methods. The normalized data were subjected to the SAM 
test [67]. The miRNAs that passed SAM were further tested by the HSD test (P < 0.05) to identify organ-specific miRNAs. 
Each column represents one hybridization and each row represents one miRNA. The figure was drawn by Treeview. Red rep-
resents positive values, green negative values, and black zero. The number of miRNAs for each organ is: Lung 2; heart 6; brain 
13; liver 5; kidney 2 and spleen 18. (B) Summary of differently expressed miRNAs among 6 organs. The number beside each 
organ represents the number of miRNAs that are expressed significantly higher in this organ than any other organs (P < 0.05). 
The number on the line between any two organs is the quantity of miRNAs expressed significantly higher in these two organs 
than in other organs (P < 0.05).
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Northern blot validationFigur  4
Northern blot validation. 15 μg total RNA was separated on a denaturing 15% PAGE gel. The 32P labeled probes for the 
microRNA were hybridized to the membrane overnight. The U6 snRNA was probed as the loading control after the hybridiza-
tion of microRNA probes. (a) lung-specific miRNAs; (b) kidney-specific miRNAs; (c) co-expressed miRNAs in the lung and 
heart identified by HSD; (d) miRNAs highly expressed in the lung and/or the heart. (e) commonly expressed miRNAs.
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Comparison between results from the microarray and Northern blotsFigure 5
Comparison between results from the microarray and Northern blots. The Northern blots in Figure 4 were quanti-
tated by the Personal Molecular Imager® FX and normalized to U6. Y axes represent the normalized intensities in the North-
ern blots or the normalized ratios in the microarrays divided by the average of those from 6 organs. The microarray data 
shown are means ± S.E. from 8 hybridizations. (a) lung-specific miRNAs; (b) kidney-specific miRNAs; (c) co-expressed miRNAs 
in the lung and heart identified by HSD; (d) miRNAs highly expressed in the lung and/or the heart. (e) commonly expressed 
miRNAs.
BMC Genomics 2007, 8:29 http://www.biomedcentral.com/1471-2164/8/29The quality of enriched small RNA was determined on a
denaturing 15% polyacrylamide gel, and the quality of
total RNA was tested on a 1% agarose gel.
miRNA labeling and microarray hybridization
The labeling and hybridization of miRNA were performed
with the 3 DNA array900 miRNA direct kit (Genisphere,
Hatfield, PA), according to the manufacturer's protocol.
Enriched small RNA (120 ng) was used for each hybridi-
zation. First, the miRNA was tailed with poly A by PAP
enzyme (poly (A) polymerase). Then the capture
sequence was ligated to the tailed miRNA. Tagged miRNA
was purified with the MinElute PCR Purification Kit (Qia-
gen, Valencia, CA). All of the small RNA samples were sep-
arately labeled with Cy3 or Cy5 capture sequence. After
labeling and purification, equal amounts of small RNA
from all the samples, labeled with the same dye, were
pooled together as a common reference. The hybridiza-
tion was performed as previously described [54]. To each
block, one labeled sample was hybridized along with a
common reference labeled with the other dye. Dye-swap
was performed to eliminate dye bias. Tagged miRNA
hybridizations were performed at 52°C overnight, and
then the slide was washed 15 min in pre-warmed 2 × SSC,
0.2% SDS, followed by 12 min in 2 × SSC at room temper-
ature and finally for 12 min in 0.2 × SSC at room temper-
ate. The 3 DNA hybridization was performed at 62°C for
4 h, and then the slide was washed and dried.
Microarray data analysis
The hybridized slides were scanned with ScanArray
Express (PerkinElmer Life and Analytical Sciences, Bos-
ton, MA), and the images were analyzed with GenePix 5.0
pro (Axon Instruments, Inc. Union City, CA). The signal
from each spot was normalized to the average signal of the
whole block. The highest and lowest signals from the 6
identical probes in the same block were excluded from the
data analysis. The geometric average of the other 4 signals
was considered to be the signal of that particular miRNA.
The ratio of the sample signal to the reference signal was
log2 transformed. A quality test was performed with the
software, Realspot, developed in our laboratory [52]. The
miRNAs with an average quality index of <1 were filtered.
The miRNAs that passed the quality test were analyzed
with SAM (Significant Analysis of Microarray) in order to
choose miRNAs that were significantly changed between
different organs (q < 0.01) [53]. These miRNAs were then
subject to the Tukey Honestly Significant Difference
(HSD) test (p < 0.05) [54]. The organ specificity index
(OSI) was also used to determine the relative specificity of
miRNA in organs. The OSI was defined as the correlation
coefficient of miRNA expression between a miRNA and a
putative miRNA whose expression levels were given the
value of 1,000 in prominent organs and a value of 0 in
other organs [54].
Northern blot analysis
Total RNA from the same organ was pooled together. The
probe sequences were exactly the same as the antisense
sequences to miRNAs except that those with sequences
which started with C were capped with G or T at the 5' end
to increase 32P labeling efficiency. RNA samples were
denatured at 95°C for 4 minutes. 15 μg total RNA was
separated on a 15% denaturing PAGE gel at 100 V for 2 h
in 1 × TBE buffer. The RNA was then transferred to a
Hybond-N+ membrane (Amersham, Piscataway, NJ)
using a Trans-blot SD semi-dry transfer cell (Bio-Rad, Her-
cules, CA) at 20 ~ 25 V for 1 hour using 0.25 × TBE as a
transfer buffer. Membranes were UV crosslinked with a
120 mJ burst and then baked at 80°C for 1 hour. For each
sample, 20 pmol antisense oligonucleotide probes were
end labeled by γ32P dATP (>7000 Ci/mmol, MP Biomedi-
cal, Irvine, CA) with T4 polynucleotide kinase (NEB, Ips-
wich, MA) for 4 hours at 37°C. The reactions were
stopped with 2 μl 0.5 M EDTA. The probes were then puri-
fied with a G-25 MicroSpin column (Amersham). Pre-
hybridization and hybridization were carried out at 30°C
using ULTRAhyb-Oligo hybridization buffer (Ambion),
according to the manufacturer's manual. After hybridiza-
tion the membranes were washed twice with 2 × SSC 0.5%
SDS for 30 minutes at 30°C. The membranes were then
exposed to a phosphor screen overnight and scanned with
the Personal Molecular Imager® FX (Bio-Rad). U6 was
probed as a loading control and only exposed to the phos-
phor screen for 5 to 10 minutes.
Authors' contributions
YW carried out microRNA microarray printing, hybridiza-
tion, data analysis and northern blot and drafted the man-
uscript. TW participated in the array printing and data
analysis. DM participated in northern blot analysis. ZC
participated in data analysis. NRC participated in sample
collection. LL conceived of the study, and participated in
its design and coordination and helped to draft the man-
uscript. All authors read and approved the final manu-
script.
Acknowledgements
We thank Dr. Heidi Stricker for editorial assistance. This work was sup-
ported by NIH R01 HL-052146, R01 HL-071628 and R01 HL-083188 (To 
LL).
References
1. Bartel DP: MicroRNAs: genomics, biogenesis, mechanism,
and function.  Cell 2004, 116:281-297.
2. He L, Hannon GJ: MicroRNAs: small RNAs with a big role in
gene regulation.  Nat Rev Genet 2004, 5:522-531.
3. Lee Y, Ahn C, Han J, Choi H, Kim J, Yim J, Lee J, Provost P, Radmark
O, Kim S, Kim VN: The nuclear RNase III Drosha initiates
microRNA processing.  Nature 2003, 425:415-419.
4. Yi R, Qin Y, Macara IG, Cullen BR: Exportin-5 mediates the
nuclear export of pre-microRNAs and short hairpin RNAs.
Genes Dev 2003, 17:3011-3016.Page 12 of 14
(page number not for citation purposes)
BMC Genomics 2007, 8:29 http://www.biomedcentral.com/1471-2164/8/295. Lee Y, Jeon K, Lee JT, Kim S, Kim VN: MicroRNA maturation:
stepwise processing and subcellular localization.  EMBO J 2002,
21:4663-4670.
6. Khvorova A, Reynolds A, Jayasena SD: Functional siRNAs and
miRNAs exhibit strand bias.  Cell 2003, 115:209-216.
7. Doench JG, Petersen CP, Sharp PA: siRNAs can function as miR-
NAs.  Genes Dev 2003, 17:438-442.
8. Lin SY, Johnson SM, Abraham M, Vella MC, Pasquinelli A, Gamberi C,
Gottlieb E, Slack FJ: The C elegans hunchback homolog, hbl-1,
controls temporal patterning and is a probable microRNA
target.  Dev Cell 2003, 4:639-650.
9. Lee RC, Feinbaum RL, Ambros V: The C. elegans heterochronic
gene lin-4 encodes small RNAs with antisense complemen-
tarity to lin-14.  Cell 1993, 75:843-854.
10. Moss EG, Lee RC, Ambros V: The cold shock domain protein
LIN-28 controls developmental timing in C. elegans and is
regulated by the lin-4 RNA.  Cell 1997, 88:637-646.
11. Chen X: A microRNA as a translational repressor of
APETALA2 in Arabidopsis flower development.  Science 2004,
303:2022-2025.
12. Giraldez AJ, Mishima Y, Rihel J, Grocock RJ, Van DS, Inoue K, Enright
AJ, Schier AF: Zebrafish MiR-430 promotes deadenylation and
clearance of maternal mRNAs.  Science 2006, 312:75-79.
13. Llave C, Xie Z, Kasschau KD, Carrington JC: Cleavage of Scare-
crow-like mRNA targets directed by a class of Arabidopsis
miRNA.  Science 2002, 297:2053-2056.
14. Wu L, Fan J, Belasco JG: MicroRNAs direct rapid deadenylation
of mRNA.  Proc Natl Acad Sci U S A 2006, 103:4034-4039.
15. Yekta S, Shih IH, Bartel DP: MicroRNA-directed cleavage of
HOXB8 mRNA.  Science 2004, 304:594-596.
16. Hornstein E, Mansfield JH, Yekta S, Hu JK, Harfe BD, McManus MT,
Baskerville S, Bartel DP, Tabin CJ: The microRNA miR-196 acts
upstream of Hoxb8 and Shh in limb development.  Nature
2005, 438:671-674.
17. Ambros V: The functions of animal microRNAs.  Nature 2004,
431:350-355.
18. Dugas DV, Bartel B: MicroRNA regulation of gene expression
in plants.  Curr Opin Plant Biol 2004, 7:512-520.
19. Wang Y, Stricker HM, Giu D, Liu L: MicroRNA: past and present.
Front Biosci 2007, 12:2316-2329.
20. Zhang B, Wang Q, Pan X: MicroRNAs and their regulatory roles
in animals and plants.  J Cell Physiol 2006.
21. Brennecke J, Hipfner DR, Stark A, Russell RB, Cohen SM: bantam
encodes a developmentally regulated microRNA that con-
trols cell proliferation and regulates the proapoptotic gene
hid in Drosophila.  Cell 2003, 113:25-36.
22. Esau C, Davis S, Murray SF, Yu XX, Pandey SK, Pear M, Watts L,
Booten SL, Graham M, McKay R, Subramaniam A, Propp S, Lollo BA,
Freier S, Bennett CF, Bhanot S, Monia BP: miR-122 regulation of
lipid metabolism revealed by in vivo antisense targeting.  Cell
Metab 2006, 3:87-98.
23. Esquela-Kerscher A, Slack FJ: Oncomirs - microRNAs with a role
in cancer.  Nat Rev Cancer 2006, 6:259-269.
24. Hammond SM: MicroRNAs as oncogenes.  Curr Opin Genet Dev
2006, 16:4-9.
25. Hatfield SD, Shcherbata HR, Fischer KA, Nakahara K, Carthew RW,
Ruohola-Baker H: Stem cell division is regulated by the micro-
RNA pathway.  Nature 2005, 435:974-978.
26. Johnston RJ, Hobert O: A microRNA controlling left/right neu-
ronal asymmetry in Caenorhabditis elegans.  Nature 2003,
426:845-849.
27. Krichevsky AM, Sonntag KC, Isacson O, Kosik KS: Specific micro-
RNAs modulate embryonic stem cell-derived neurogenesis.
Stem Cells 2006, 24:857-864.
28. Poy MN, Eliasson L, Krutzfeldt J, Kuwajima S, Ma X, Macdonald PE,
Pfeffer S, Tuschl T, Rajewsky N, Rorsman P, Stoffel M: A pancreatic
islet-specific microRNA regulates insulin secretion.  Nature
2004, 432:226-230.
29. Reinhart BJ, Slack FJ, Basson M, Pasquinelli AE, Bettinger JC, Rougvie
AE, Horvitz HR, Ruvkun G: The 21-nucleotide let-7 RNA regu-
lates developmental timing in Caenorhabditis elegans.
Nature 2000, 403:901-906.
30. Shcherbata HR, Hatfield S, Ward EJ, Reynolds S, Fischer KA, Ruohola-
Baker H: The MicroRNA pathway plays a regulatory role in
stem cell division.  Cell Cycle 2006, 5:172-175.
31. Xu P, Vernooy SY, Guo M, Hay BA: The Drosophila microRNA
Mir-14 suppresses cell death and is required for normal fat
metabolism.  Curr Biol 2003, 13:790-795.
32. Zhang B, Pan X, Anderson TA: MicroRNA: a new player in stem
cells.  J Cell Physiol 2006, 209:266-269.
33. Zhang B, Pan X, Cobb GP, Anderson TA: microRNAs as onco-
genes and tumor suppressors.  Dev Biol 2006, .:.
34. Lewis BP, Burge CB, Bartel DP: Conserved seed pairing, often
flanked by adenosines, indicates that thousands of human
genes are microRNA targets.  Cell 2005, 120:15-20.
35. Babak T, Zhang W, Morris Q, Blencowe BJ, Hughes TR: Probing
microRNAs with microarrays: tissue specificity and func-
tional inference.  RNA 2004, 10:1813-1819.
36. Barad O, Meiri E, Avniel A, Aharonov R, Barzilai A, Bentwich I, Einav
U, Gilad S, Hurban P, Karov Y, Lobenhofer EK, Sharon E, Shiboleth
YM, Shtutman M, Bentwich Z, Einat P: MicroRNA expression
detected by oligonucleotide microarrays: system establish-
ment and expression profiling in human tissues.  Genome Res
2004, 14:2486-2494.
37. Baskerville S, Bartel DP: Microarray profiling of microRNAs
reveals frequent coexpression with neighboring miRNAs and
host genes.  RNA 2005, 11:241-247.
38. Krichevsky AM, King KS, Donahue CP, Khrapko K, Kosik KS: A
microRNA array reveals extensive regulation of microRNAs
during brain development.  RNA 2003, 9:1274-1281.
39. Liang RQ, Li W, Li Y, Tan CY, Li JX, Jin YX, Ruan KC: An oligonu-
cleotide microarray for microRNA expression analysis based
on labeling RNA with quantum dot and nanogold probe.
Nucleic Acids Res 2005, 33:e17.
40. Liu CG, Calin GA, Meloon B, Gamliel N, Sevignani C, Ferracin M,
Dumitru CD, Shimizu M, Zupo S, Dono M, Alder H, Bullrich F,
Negrini M, Croce CM: An oligonucleotide microchip for
genome-wide microRNA profiling in human and mouse tis-
sues.  Proc Natl Acad Sci U S A 2004, 101:9740-9744.
41. Miska EA, varez-Saavedra E, Townsend M, Yoshii A, Sestan N, Rakic
P, Constantine-Paton M, Horvitz HR: Microarray analysis of
microRNA expression in the developing mammalian brain.
Genome Biol 2004, 5:R68.
42. Nelson PT, Baldwin DA, Scearce LM, Oberholtzer JC, Tobias JW,
Mourelatos Z: Microarray-based, high-throughput gene
expression profiling of microRNAs.  Nat Methods 2004,
1:155-161.
43. Thomson JM, Parker J, Perou CM, Hammond SM: A custom micro-
array platform for analysis of microRNA gene expression.
Nat Methods 2004, 1:47-53.
44. Schmittgen TD, Jiang J, Liu Q, Yang L: A high-throughput method
to monitor the expression of microRNA precursors.  Nucleic
Acids Res 2004, 32:e43.
45. Shi R, Chiang VL: Facile means for quantifying microRNA
expression by real-time PCR.  Biotechniques 2005, 39:519-525.
46. Axtell MJ, Bartel DP: Antiquity of microRNAs and their targets
in land plants.  Plant Cell 2005, 17:1658-1673.
47. Lagos-Quintana M, Rauhut R, Meyer J, Borkhardt A, Tuschl T: New
microRNAs from mouse and human.  RNA 2003, 9:175-179.
48. Moss EG: RNA interference: it's a small RNA world.  Curr Biol
2001, 11:R772-R775.
49. Pasquinelli AE, Reinhart BJ, Slack F, Martindale MQ, Kuroda MI, Maller
B, Hayward DC, Ball EE, Degnan B, Muller P, Spring J, Srinivasan A,
Fishman M, Finnerty J, Corbo J, Levine M, Leahy P, Davidson E,
Ruvkun G: Conservation of the sequence and temporal
expression of let-7 heterochronic regulatory RNA.  Nature
2000, 408:86-89.
50. Weber MJ: New human and mouse microRNA genes found by
homology search.  FEBS J 2005, 272:59-73.
51. Zhang B, Pan X, Cannon CH, Cobb GP, Anderson TA: Conserva-
tion and divergence of plant microRNA genes.  Plant J 2006,
46:243-259.
52. Chen Z, Liu L: RealSpot: Software validating results from
DNA microarray data analysis with spot images.  Physiol
Genomics 2005, 21:284-291.
53. Tusher VG, Tibshirani R, Chu G: Significance analysis of micro-
arrays applied to the ionizing radiation response.  Proc Natl
Acad Sci U S A 2001, 98:5116-5121.
54. Chen Z, Chen JW, Weng T, Jin N, Liu L: Identification of rat lung-
prominent genes by a parallel DNA microarray hybridiza-
tion.  BMC Genomics 2006, in press:.Page 13 of 14
(page number not for citation purposes)
BMC Genomics 2007, 8:29 http://www.biomedcentral.com/1471-2164/8/29Publish with BioMed Central   and  every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
55. Sempere LF, Freemantle S, Pitha-Rowe I, Moss E, Dmitrovsky E,
Ambros V: Expression profiling of mammalian microRNAs
uncovers a subset of brain-expressed microRNAs with possi-
ble roles in murine and human neuronal differentiation.
Genome Biol 2004, 5:R13.
56. Taoka M, Ichimura T, Wakamiya-Tsuruta A, Kubota Y, Araki T, Obi-
nata T, Isobe T: V-1, a protein expressed transiently during
murine cerebellar development, regulates actin polymeriza-
tion via interaction with capping protein.  J Biol Chem 2003,
278:5864-5870.
57. Chen JF, Mandel EM, Thomson JM, Wu Q, Callis TE, Hammond SM,
Conlon FL, Wang DZ: The role of microRNA-1 and microRNA-
133 in skeletal muscle proliferation and differentiation.  Nat
Genet 2006, 38:228-233.
58. Jopling CL, Yi M, Lancaster AM, Lemon SM, Sarnow P: Modulation
of hepatitis C virus RNA abundance by a liver-specific Micro-
RNA.  Science 2005, 309:1577-1581.
59. Tanzer A, Stadler PF: Molecular evolution of a microRNA clus-
ter.  J Mol Biol 2004, 339:327-335.
60. Hayashita Y, Osada H, Tatematsu Y, Yamada H, Yanagisawa K, Tom-
ida S, Yatabe Y, Kawahara K, Sekido Y, Takahashi T: A polycistronic
microRNA cluster, miR-17-92, is overexpressed in human
lung cancers and enhances cell proliferation.  Cancer Res 2005,
65:9628-9632.
61. He L, Thomson JM, Hemann MT, Hernando-Monge E, Mu D, Good-
son S, Powers S, Cordon-Cardo C, Lowe SW, Hannon GJ, Hammond
SM: A microRNA polycistron as a potential human oncogene.
Nature 2005, 435:828-833.
62. Takamizawa J, Konishi H, Yanagisawa K, Tomida S, Osada H, Endoh
H, Harano T, Yatabe Y, Nagino M, Nimura Y, Mitsudomi T, Takahashi
T: Reduced expression of the let-7 microRNAs in human lung
cancers in association with shortened postoperative survival.
Cancer Res 2004, 64:3753-3756.
63. Harris KS, Zhang Z, McManus MT, Harfe BD, Sun X: Dicer function
is essential for lung epithelium morphogenesis.  Proc Natl Acad
Sci U S A 2006, 103:2208-2213.
64. Lu J, Qian J, Chen F, Tang X, Li C, Cardoso WV: Differential
expression of components of the microRNA machinery dur-
ing mouse organogenesis.  Biochem Biophys Res Commun 2005,
334:319-323.
65. Karube Y, Tanaka H, Osada H, Tomida S, Tatematsu Y, Yanagisawa K,
Yatabe Y, Takamizawa J, Miyoshi S, Mitsudomi T, Takahashi T:
Reduced expression of Dicer associated with poor prognosis
in lung cancer patients.  Cancer Sci 2005, 96:111-115.
66. Yanaihara N, Caplen N, Bowman E, Seike M, Kumamoto K, Yi M,
Stephens RM, Okamoto A, Yokota J, Tanaka T, Calin GA, Liu CG,
Croce CM, Harris CC: Unique microRNA molecular profiles in
lung cancer diagnosis and prognosis.  Cancer Cell 2006,
9:189-198.
67. Website title [http://www-stat.stanford.edu/~tibs/SAM/].
2007.Page 14 of 14
(page number not for citation purposes)
